Tesamorelin 10mg
Tesamorelin
CAS: 218949-48-5
Tesamorelin is a stabilized GHRH analog (GHRH + trans-3-hexenoic acid modification) with FDA approval for HIV-associated lipodystrophy. Demonstrated significant visceral adipose tissue reduction in clinical trials. 99.1% HPLC purity.
Specifications
For laboratory research use only. Not for human consumption.
Mechanism of Action
GHRH receptor agonist that stimulates GH pulsatility with particular downstream effects on visceral fat reduction via GH-mediated lipolysis. The trans-3-hexenoic acid modification enhances plasma stability versus native GHRH.
Research FAQ
What distinguishes Tesamorelin from other GHRH analogs?
Tesamorelin has clinical-grade validation for visceral fat reduction (HARP trial: -15% VAT) and is the only FDA-approved GHRH analog — giving it the strongest clinical evidence base in its class.
